---
title: "BRIEF: CStone raises $134 million in share placement at 7% discount"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/282833915.md"
description: "CStone Pharmaceuticals 宣布将以每股 HK$8.97 的价格发行 1.18 亿新股，筹集约 HK$10.5 亿（约合 1.34 亿美元），折扣约为前一交易日收盘价的 6.95%。此次融资的约 90% 将用于支持其 “Pipeline 2.0” 肿瘤药物开发，包括三特异性抗体 CS2009 和 ROR1 ADC 候选药物 CS5001，其余资金将用于一般营运资金。"
datetime: "2026-04-15T11:20:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282833915.md)
  - [en](https://longbridge.com/en/news/282833915.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282833915.md)
---

# BRIEF: CStone raises $134 million in share placement at 7% discount

Drugmaker **CStone Pharmaceuticals** (2616.HK) **announced** on Wednesday it will place 118 million new shares at HK$8.97 each, representing about 7.4% of its enlarged share capital. The placement price reflects a discount of about 6.95% to the previous trading day’s close, with the sale expected to generate net proceeds of about HK$1.05 billion ($134 million).

The company said about 90% of the proceeds will be used to fund its “Pipeline 2.0” oncology drug development, including the trispecific antibody CS2009 and the ROR1 ADC candidate CS5001, with the remainder allocated for general working capital.

According to earlier disclosures, CS2009 is currently in Phase I/II clinical trials and is expected to enter global Phase Three multi-regional clinical trials by the end of this year, targeting indications such as non-small cell lung cancer, colorectal cancer and small cell lung cancer.

The company reported revenue of 270 million yuan last year, down 33.8% year-on-year, while its net loss widened sharply from 91.2 million yuan to 437 million yuan. The increase was mainly due to channel compensation expenses related to one of its product’s inclusion on China’s National Reimbursement Drug List, as well as margin pressure and a 131% surge in R&D spending to 312 million yuan.

CStone’s shares opened lower on Wednesday and were trading at HK$9.43 by the midday break, down 2.18%. The stock is up more than 77% so far this year.

_By Lee Shih Ta_

_To subscribe to Bamboo Works weekly free newsletter, click_ _here_

### 相关股票

- [02616.HK](https://longbridge.com/zh-CN/quote/02616.HK.md)
- [513700.CN](https://longbridge.com/zh-CN/quote/513700.CN.md)

## 相关资讯与研究

- [君实生物：JS207 已处于 II 期临床研究阶段](https://longbridge.com/zh-CN/news/286875089.md)
- [不玩烧钱扩张！基石药业断臂转型？](https://longbridge.com/zh-CN/news/283443040.md)
- [翰森制药：第四代 EGFR-TKI HS-10504 片用于非小细胞肺癌纳入突破性治疗药物](https://longbridge.com/zh-CN/news/287203617.md)
- [和铂医药-B 公布首款候选药物用于肥胖症治疗的下一代靶向 ACVR2A/2B 抗体 LET003 的临床前数据](https://longbridge.com/zh-CN/news/286688634.md)
- [从 “5 倍牛股” 到 “腰斩”！映恩生物砸出 “回购 + 增持” 救市大招](https://longbridge.com/zh-CN/news/287015582.md)